On May 30, 2024, Hengrui Pharmaceutical received the Yidu Data Purchase Rating. In the past month, Hengrui Pharmaceutical received 2 research reports.

The research report predicts: Hengrui Pharmaceutical (600276)'s main business: the company is mainly engaged in chemical drug R&D, production and sales, and currently accounts for nearly 50% of innovative drugs, leading domestic innovative drugs; performance: The company's financial data for the past three years shows that the company's performance has resumed positive growth; stock price trends: the company's stock price trend in the past year is basically consistent with the chemical pharmaceutical index trend. Beta opportunities are better, and α breakout opportunities are slightly weaker; key areas with high incidence rates, such as breast cancer, lung cancer, gastrointestinal cancer, and urinary tumors. Successfully transformed into innovative drugs, upgrading mainly from generic drugs and first generic drugs to mainly innovative drugs. With in-depth pain management, the new drug rimazolam is expected to be released. Domestic substitutions are being accelerated. Hengrui has overrated 5 contrast agents, 4 of which were the first reviews. Other sectors have a broad layout, and the harvest period is about to begin. Various treatment fields such as autoimmunity, cardiovascular disease, metabolic disease, and anti-infection. Hengrui Pharmaceutical is a typical R&D-driven enterprise. Only continuous launch of innovative drugs can support future performance revenue. R&D is expensive and has a certain risk of failure.

Risk warning: The chemical business is not very good; continuous investment in R&D and sales expenses is necessary to maintain operations.